Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-05-08Clinical Trial Update: Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension [Phase 4]
Phase 4 clinical trial update examining the effects of spironolactone on collagen metabolism in patients with pulmonary arterial hypertensio…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
A terminated clinical trial evaluating inhaled treprostinil for ventilation-perfusion matching in pulmonary arterial hypertension and chroni…
-
FDA label_change · 2015-04-30FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc., resulting in updated labeli…
-
CLINICAL_TRIALS trial_result · 2015-04-28Clinical Trial Update: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial evaluating first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension has completed with resu…
-
FDA approval · 2015-04-27FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approves a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-04-27FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2015-04-27FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA is handling a supplemental approval application for Revatio (sildenafil citrate) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Ranolazine and Pulmonary Hypertension [Phase 3]
Phase 3 trial update reporting completed results for ranolazine in patients with angina and pulmonary arterial hypertension.
-
FDA approval · 2015-04-17FDA Approved: FLOLAN — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for FLOLAN (epoprostenol sodium) submitted by GlaxoSmithKline LLC. The approval updates the drug…
-
FDA approval · 2015-04-02FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for ADCIRCA (tadalafil) submitted by United Therapeutics Corporation.
-
FDA approval · 2015-04-02FDA Approved: SILDENAFIL — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for sildenafil submitted by Macleods Pharmaceuticals Limited. This action authorizes changes und…
-
CLINICAL_TRIALS research · 2015-03-31Clinical Trial Update: Training With Whole Body Vibration Device in Patients With PAH [NA]
This clinical trial update reports a study evaluating whole-body vibration training in patients with pulmonary arterial hypertension, sponso…
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: Assessmet of Patients With PAH Right Ventricular Volume [NA]
Completed clinical trial update from VentriPoint Diagnostics assessing right ventricular volume in patients with pulmonary arterial hyperten…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension [Phase 3]
Phase III randomized trial evaluating UT-15 in patients with pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS research · 2015-03-24Clinical Trial Update: Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
A completed TyTRATE Registry study evaluating dosing and titration of Tyvaso (treprostinil) in patients with pulmonary arterial hypertension…
-
CLINICAL_TRIALS trial_result · 2015-03-23Clinical Trial Update: Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension [Phase 2, Phase 3]
This update reports the results of a Phase 2/Phase 3 study evaluating the safety and efficacy of imatinib mesylate in patients with pulmonar…
-
CLINICAL_TRIALS trial_result · 2015-03-20Clinical Trial Update: Coenzyme Q-10 and Pulmonary Arterial Hypertension [NA]
A completed clinical trial evaluating Coenzyme Q-10 for pulmonary arterial hypertension has posted its results.
-
FDA approval · 2015-03-18FDA Approved: SILDENAFIL — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approves Amneal Pharmaceuticals of New York LLC's supplemental application for a generic sildenafil product.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Drug Interaction Between Ritonavir And Sitaxsentan [Phase 1]
Phase 1 trial assessing the drug interaction between ritonavir and sitaxsentan for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan [Phase 1]
Phase 1 study assessing the effect of rifampin on the pharmacokinetics of sitaxsentan has been withdrawn.
-
FDA approval · 2015-03-03FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for VELETRI (epoprostenol) from Actelion Pharmaceuticals US, Inc., reflecting an update to the produ…
-
FDA approval · 2015-02-23FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved Bayer HealthCare Pharmaceuticals Inc.'s supplemental application for ADEMPAS (riociguat).
-
FDA label_change · 2015-02-03FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for Revatio (sildenafil citrate) by Pfizer Laboratories Division Pfizer Inc, resulting in an approve…
-
CLINICAL_TRIALS trial_result · 2015-02-02Clinical Trial Update: Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
This trial update presents long-term safety and efficacy observations for inhaled iloprost (Ventavis) in patients with primary pulmonary art…
-
CLINICAL_TRIALS trial_result · 2015-01-26Clinical Trial Update: Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) [Phase 4]
Phase 4 trial comparing bosentan plus sildenafil versus sildenafil alone in pulmonary arterial hypertension; results have been posted.